NCT06212245View on ClinicalTrials.gov

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 25, 2024

Primary Completion Date

December 25, 2024

Study Completion Date

June 25, 2025

Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
DRUG

Inebilizumab

Participants will receive IV inebilizumab 300 mg

Trial Locations (1)

100000

IRB of Beijing Tiantan Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
collaborator

Horizon Therapeutics Ireland DAC

INDUSTRY

lead

Hansoh BioMedical R&D Company

INDUSTRY